The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance

Bibliographic Details
Main Authors:	David, Justin, Hamilton, Duane, Schlom, Jeffrey, Palena, Claudia
Format:	Online
Language:	English
Published:	BioMed Central 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288654/

Similar Items

Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
by: David, Justin M, et al.
Published: (2015)

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition
by: David, Justin M., et al.
Published: (2016)

Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target
by: Palena, Claudia, et al.
Published: (2013)

Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody
by: Hamilton, Duane H., et al.
Published: (2014)

High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack
by: Hamilton, Duane H, et al.
Published: (2013)

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
by: Hamilton, Duane H., et al.
Published: (2013)

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
by: Boyerinas, Benjamin, et al.
Published: (2013)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
by: Heery, Christopher R, et al.
Published: (2015)

The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies
by: Huang, B, et al.
Published: (2013)

The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
by: David, Justin M., et al.
Published: (2016)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
by: Jochems, Caroline, et al.
Published: (2013)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
by: Donahue, Renee N, et al.
Published: (2014)

Specific immunotherapy of MUC1-positive adenocarcinomas with a recombinant vaccinia virus expressing MUC1 and IL-2
by: Bizouarne, N, et al.
Published: (2001)

From Notochord Formation to Hereditary Chordoma: The Many Roles of Brachyury
by: Nibu, Yutaka, et al.
Published: (2013)

Brachyury, Foxa2 and the cis-Regulatory Origins of the Notochord
by: José-Edwards, Diana S., et al.
Published: (2015)

MUC1 alters oncogenic events and transcription in human breast cancer cells
by: Hattrup, Christine L, et al.
Published: (2006)

Development of breast cancer immunotherapy using MUC1 retargeted T lymphocytes
by: Wilkie, S, et al.
Published: (2006)

Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes
by: Wilkie, S, et al.
Published: (2008)

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
by: Fernando, Romaine I., et al.
Published: (2016)

The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer
by: Duncan, Timothy J, et al.
Published: (2007)

Interleukin-8 drives epithelial-mesenchymal transition of human carcinomas
by: Fernando, Romaine I, et al.
Published: (2013)

An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
by: Palena, Claudia, et al.
Published: (2014)

Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
by: Yosuke Miura, et al.
Published: (2018-07-01)

Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
by: Kim, Peter S, et al.
Published: (2014)

MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance
by: Betge, Johannes, et al.
Published: (2016)

Expression of MUC1 and MUC4 in Gallbladder Adenocarcinoma
by: Kim, Su-Mi, et al.
Published: (2012)

Genomic Targets of Brachyury (T) in Differentiating Mouse Embryonic Stem Cells
by: Evans, Amanda L., et al.
Published: (2012)

An Intact Brachyury Function Is Necessary to Prevent Spurious Axial Development in Xenopus laevis
by: Aguirre, Cecilia E., et al.
Published: (2013)

Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma
by: Zhang, Linlin, et al.
Published: (2013)

Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas
by: WANG, KE, et al.
Published: (2015)

Oncogenic cancer/testis antigens: prime candidates for immunotherapy
by: Gjerstorff, Morten F., et al.
Published: (2015)

Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer
by: Pinto, Filipe, et al.
Published: (2016)

Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression
by: Li, Guangchao, et al.
Published: (2014)

Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas
by: Do, Sung-Im, et al.
Published: (2013)

Natural and Induced Humoral Responses to MUC1
by: von Mensdorff-Pouilly, Silvia, et al.
Published: (2011)

Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)
by: Hanson, Ryan L., et al.
Published: (2016)

BRACHYURY and CDX2 Mediate BMP-Induced Differentiation of Human and Mouse Pluripotent Stem Cells into Embryonic and Extraembryonic Lineages
by: Bernardo, Andreia S., et al.
Published: (2011)

Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma
by: Du, Rui, et al.
Published: (2014)

Comparison of the Transmembrane Mucins MUC1 and MUC16 in Epithelial Barrier Function
by: Gipson, Ilene K., et al.
Published: (2014)

Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer
by: Shindo, Yoshitaro, et al.
Published: (2014)